Lee Hankil, Kang Hye-Young, Cho Sunghwa, Park Seonyoung, Kim Ah-Young, Jung Sun-Young, Seong Baik Lin, Lee Young-Mock
Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon 21983, Korea.
Vaccines (Basel). 2020 Feb 24;8(1):101. doi: 10.3390/vaccines8010101.
South Korea operates a National Vaccine Injury Compensation Program (VICP) for people who experience adverse events following immunization (AEFI). To run this program rationally, it is a prerequisite to confirm whether adverse events were caused by immunization. Guillain-Barré syndrome (GBS), a severe neurological disease with limb pain and muscle weakness as cardinal symptoms, is attracting attention as an AEFI. However, algorithm or guidelines for assessing the causality between vaccination and the incidence of GBS are lacking. We aimed to develop guidelines for causality assessment of GBS as an AEFI and suggest using these guidelines in alignment with the VICP. We systematically searched for other previously published algorithms or guidelines and found a WHO-AEFI guideline used worldwide; however, it only provides general instructions and is not tailored to specific adverse events. We translated and locally adapted the structure of this guideline and then added contents related to GBS. The GBS-specific guideline consists of four steps: case ascertainment of GBS, checklist (including (1) order of incidence, (2) temporal proximity, (3) evidence for other causes and (4) published evidence), an algorithm, and final classification. We listed key information on confirming GBS and whether any other causes of GBS were present. For real world application of the guideline along with the VICP, we collaborated with a panel of neurologists, epidemiologic investigators, and committee members from the VICP. To ensure transparency and a scientific approach, regular updates and collaboration with neurologists are essential. We expect that this guideline will contribute to logical causality assessment and compensation decisions for GBS and will provide the basic structure for causality assessment of other AEFIs.
韩国为经历免疫接种后不良事件(AEFI)的人群实施了国家疫苗伤害补偿计划(VICP)。为合理运行该计划,确认不良事件是否由免疫接种引起是一个先决条件。吉兰-巴雷综合征(GBS)是一种以肢体疼痛和肌肉无力为主要症状的严重神经系统疾病,作为一种AEFI正受到关注。然而,缺乏用于评估疫苗接种与GBS发病率之间因果关系的算法或指南。我们旨在制定GBS作为AEFI的因果关系评估指南,并建议结合VICP使用这些指南。我们系统地搜索了其他先前发表的算法或指南,发现了一项在全球范围内使用的WHO-AEFI指南;然而,它仅提供一般说明,并未针对特定不良事件进行定制。我们翻译并在本地调整了该指南的结构,然后添加了与GBS相关的内容。GBS特异性指南包括四个步骤:GBS病例确定、检查表(包括(1)发病顺序、(2)时间接近度、(3)其他原因的证据和(4)已发表的证据)、一种算法以及最终分类。我们列出了确认GBS以及是否存在GBS其他病因的关键信息。为使该指南能与VICP一起在实际应用中发挥作用,我们与一组神经科医生、流行病学调查人员以及VICP的委员会成员进行了合作。为确保透明度和科学方法,定期更新以及与神经科医生的合作至关重要。我们期望该指南将有助于对GBS进行合理的因果关系评估和补偿决策,并将为其他AEFI的因果关系评估提供基本结构。